Villet Stéphanie, Vacher Véronique, Colas Aurélie, Danno Karine, Masson Jean-Louis, Marijnen Philippe, Bordet Marie-France
Laboratoires Boiron, 2 Avenue de l'Ouest Lyonnais, 69510 Messimy, France.
Laboratoires Boiron, 2 Avenue de l'Ouest Lyonnais, 69510 Messimy, France.
Homeopathy. 2016 Feb;105(1):84-91. doi: 10.1016/j.homp.2015.07.002. Epub 2015 Aug 29.
Anxiety and sleep disorders (SDS) are frequently treated with psychotropic drugs. Health authorities in France have been advised to improve access to alternative treatments such as homeopathic medicines. Our aim was to describe the socio-demographic characteristics and clinical progression of patients prescribed homeopathic medicine Passiflora Compose (PC) for anxiety and/or SDS.
This was an open-label, observational study. Randomly selected general practitioners (GPs) known to prescribe homeopathic medicines recruited consecutive patients (≥18-years) prescribed PC. The following data were recorded at inclusion by the GP: socio-demographic data and anxiety severity (Hamilton anxiety rating scale or HAM-A); and by the patients: level of anxiety (STAI Spielberger self-assessment questionnaire) and SDS (Jenkins sleep scale or JSS). Anxiety and SDS were reassessed after 4 weeks of treatment using the same scales.
A total of 639 patients (mean age: 46.3 ± 17.5 years; 78.6% female) were recruited by 98 GPs. Anxiety was present in 85.4% (HAM-A) and 93.3% (Spielberger State) at inclusion (mean scores: 17.8 ± 8.91 and 54.59 ± 11.69, respectively) and SDS was present in 74.0% (mean score: 15.24 ± 5.28). A total of 401 (62.7%) patients received PC alone and 167 (26.1%) PC + psychotropics. After 4 weeks, mean anxiety scores decreased by more than 7, 12 and 6 points (HAM-A, Spielberger State and Trait respectively), and SDS score by more than 4 points (JSS).
Anxiety and/or SDS improved significantly in patients included on this study. PC could be an alternative to the use of psychotropic drugs for first intention treatment of anxiety and SDS. Further studies are needed to confirm those results.
焦虑症和睡眠障碍(SDS)通常使用精神药物进行治疗。法国卫生当局已被建议改善获得替代疗法的途径,如顺势疗法药物。我们的目的是描述开具顺势疗法药物西番莲复方(PC)用于治疗焦虑症和/或SDS的患者的社会人口学特征和临床进展。
这是一项开放标签的观察性研究。随机选择已知开具顺势疗法药物的全科医生(GP)招募连续的(≥18岁)开具PC的患者。GP在纳入时记录以下数据:社会人口学数据和焦虑严重程度(汉密尔顿焦虑评定量表或HAM - A);患者记录:焦虑水平(斯皮尔伯格状态 - 特质焦虑问卷或STAI)和SDS(詹金斯睡眠量表或JSS)。治疗4周后使用相同量表重新评估焦虑症和SDS。
98名全科医生共招募了639名患者(平均年龄:46.3±17.5岁;78.6%为女性)。纳入时,85.4%(HAM - A)和93.3%(斯皮尔伯格状态)存在焦虑(平均得分分别为:17.8±8.91和54.59±11.69),74.0%存在SDS(平均得分:15.24±5.28)。共有401名(62.7%)患者仅接受PC治疗,167名(26.1%)患者接受PC +精神药物治疗。4周后,平均焦虑得分分别下降超过7分、12分和6分(分别为HAM - A、斯皮尔伯格状态和特质),SDS得分下降超过4分(JSS)。
本研究纳入的患者中焦虑症和/或SDS有显著改善。PC可作为焦虑症和SDS初始治疗中使用精神药物的替代方法。需要进一步研究来证实这些结果。